Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave Shuffles Top Brass; HistoRx Ramps Up; Watlington Exits Biosite; Ando Leaves Decode; Hawkins to Europe; and Others

Third Wave Technologies announced managerial changes yesterday associated with CEO Kevin Conroy's recent succession.

 

Maneesh Arora will transition to the position of chief financial officer by mid-March, the company said. James Herrman will retain the title through the company's annual report filing.

 

Gregory Hamilton has been named vice president of finance.

 

John Bellano has been appointed vice president of sales, succeeding Jake Orville. Orville will transition to an as-yet undisclosed position in the company.

 

Arora joined Third Wave in January 2003 and served, most recently as vice president of marketing and strategy. His previous positions include director of corporate strategy and new ventures and Ondeo Nalco and a range of finance, marketing and sales roles at Kraft Foods.

 

Hamilton joined the company from Leo Burnett. Prior to that he was an auditor and consultant at Arthur Andersen and Accenture.

 

Bellano joined Third Wave in February as regional vice president of sales from Roche Diagnostics, where he was a regional business manager since 2000.


HistoRx has added three senior managers to focus on its Aqua platform, the company announced yesterday.

 

The new team includes Donna Marino, vice president of diagnostics, Lorah Perlee, president of technical operations, and Robert Tuttle, director of bioinformatics.

 

Marino comes to HistoRx from Genomic Healthcare Strategies, where she was a principle. She has also held positions at the Unite Acquisition Group, Unilever, Grand Metropolitan and Laderle Laboratories. At HistoRx she will lead the diagnostics business unit and hire a team to bring the tests to market.

 

Perlee was previously director of scientific applications at Protedyne. She has also held positions at Molecular Staging, DiagXotics and Lifecodes. At HistoRx Perlee will oversee core services.

 

Tuttle was previouslt at CuraGen as bioinformatics systems manager. He has held senior positions at Turbogenomics and Gerber Scientific. He will lead commercial development of HistoRx's Aqua platform.


Tom Watlington, executive vice president and chief operating officer of Biosite, will leave the company by the end of the first quarter, Biosite said last week.

 

Watlington leaves to take an executive position at Sanderling Ventures, the company said.


Decode announced Monday that Goran Ando has resigned from the board of directors. He joined the board in February 2004.


Trevor Hawkins  stepped down yesterday as president and CEO of MDS to take a position in Europe with Phillips, MDS told GenomeWeb today.

 

Hawkins has also resigned from the board of Tm Bioscience, said Tm in a statement released today.


Ambit Biosciences has named Donald Myll senior vice president commercial operations and chief financial officer and Stephen Keane vice president, corporate development, the company said last week.

 

Myll was previously chief financial officer of AMN Healthcare. He has held senior positions at Daou Systems, Hearing Science, and TheraTx.

 

Keane held senior development positions at Dendreon, Vorvas, Epimmune, Sibia Neurosciences and Molecular Biosystems.


Illumina named Matt Posard vice president of marketing, the company said today.

 

Posard comes to the company with six years of sales and marketing experience at Biosite. He has also held various marketing positions at GenbProbe.


EraGen has named Greg Johnson, Tracy Marshbanks, and Buce Neviaser to the company's board of directors, EraGen said Monday.

 

Johnson is the managing director of Prolog Ventures.

 

Tracy Marshbanks is vice president of First Analysis.

 

Bruce Neviaser is a general partner at Continuum Investment.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.